Fundraising Fox

Mark Rosenblum

Executive at Nocion Therapeutics · Executive Vice President, Chief Financial Officer at Salarius Pharmaceuticals · Executive at Decoy Therapeutics

Greater Boston

Find your path to Mark

1,190 people in our graph share verified history with Mark — schools, employers, funds. One of them is your warm intro.

Wesley ChanunlockedMark: together at Massachusetts Institute of Technology (1998–2001)
×9Mark: together at Massachusetts Institute of Technology
×2Mark: together at Cornell

About

Mark Rosenblum is Chief Technology Officer and Co-Founder at Decoy Therapeutics Inc., a role he assumed in July 2023, with over two decades of experience in pharmaceutical development and drug delivery technologies. He previously served as Senior Vice President of Pharmaceutical Development at Nocion Therapeutics and as Head of Pharmaceutical Development at Civitas Therapeutics, where he led CMC activities for Inbrija, approved by the FDA in 2018 for OFF episodes in Parkinson's Disease; earlier roles included positions at Pulmatrix, Alkermes, and Advanced Inhalation Research. He holds a B.S. in Chemical Engineering from Cornell University and a Ph.D. in Chemical Engineering and Materials Science from the University of California, Santa Barbara, and completed an NIH Postdoctoral Fellow

Executive at Nocion Therapeutics

Intro paths

→

In turn, Mark can intro founders to Nocion Therapeutics's investors below.

Nocion Therapeutics's investors · 6

Canaan PartnersStamford · $500K – $20M checks · since 2025F-Prime CapitalCambridge · $3M – $10M checks · since 2024Mission BiocapitalSan Francisco · $500K checks · since 2024Monograph Capital PartnersLondon · since 2025Osage University PartnersBala Cynwyd · since 2024OUP (Osage University Partners)Bala Cynwyd · $1M – $20M checks

Executive Vice President, Chief Financial Officer at Salarius Pharmaceuticals

Co-founders at Salarius Pharmaceuticals

CW
Christoph WestphalExecutive Officer, Director

Executive at Decoy Therapeutics

Experience

  1. Decoy Therapeutics Inc.Chief Technology Officer, Co-Foundercurrent2023 — presentCambridge, Massachusetts, United States
  2. Nocion Therapeutics, Inc.Senior Vice President, Pharmaceutical Development2019 — 2023Waltham, MA
  3. Acorda Therapeutics, Inc.Senior Vice President, Pharmaceutical Development & Technical Operations, Site Head2014 — 2019Waltham, MA
  4. Civitas Therapeutics (Acquired by Acorda Therapeutics)Vice President of Development2011 — 2014Chelsea, MA
  5. Pulmatrix Inc.Vice President, Development and IP2007 — 2011Lexington, MA
  6. AlkermesDirector, Formulation Development2000 — 2007
  7. Advanced Inhalation Research Inc. (Acquired by Alkermes)Senior Scientist1998 — 1999

Skills & more

Pharmaceutical Industry6Biotechnology13Lifesciences2Drug Development9Drug Delivery4Technology Transfer10Clinical Development2Drug Discovery1Formulation3Life Sciences1R&D4Research and Development (R&D)1

From Mark's professional profile.

Frequently asked questions

Who is Mark Rosenblum?
Mark Rosenblum is Chief Technology Officer and Co-Founder at Decoy Therapeutics Inc., a role he assumed in July 2023, with over two decades of experience in pharmaceutical development and drug delivery technologies. He previously served as Senior Vice President of Pharmaceutical Development at Nocion Therapeutics and as Head of Pharmaceutical Development at Civitas Therapeutics, where he led CMC activities for Inbrija, approved by the FDA in 2018 for OFF episodes in Parkinson's Disease; earlier roles included positions at Pulmatrix, Alkermes, and Advanced Inhalation Research. He holds a B.S. in Chemical Engineering from Cornell University and a Ph.D. in Chemical Engineering and Materials Science from the University of California, Santa Barbara, and completed an NIH Postdoctoral Fellow
Where does Mark Rosenblum work?
Mark Rosenblum is Executive at Nocion Therapeutics and Executive Vice President, Chief Financial Officer at Salarius Pharmaceuticals and Executive at Decoy Therapeutics.
Where did Mark Rosenblum go to school?
Mark Rosenblum studied at Massachusetts Institute of Technology (Research Affiliate, Langer Laboratory); Massachusetts Institute of Technology/Harvard University (Post-Doctoral, Chemical Engineering); UC Santa Barbara (Ph.D., Chemical Engineering).

Same school

Also attended Massachusetts Institute of Technology2,000

Hemant TanejaCEO & Managing Director of General CatalystNat FriedmanCo-lead of Meta Superintelligence Labs; co-founder of NFDGBrad FeldCo-founder of Foundry and TechstarsMatt HuangCo-founder and Managing Partner at ParadigmDelian AsparouhovPartner at Founders Fund and co-founder of VardaDrew HoustonCo-founder & CEO of Dropbox

+ 1,994 more

Also attended UC Santa Barbara437

Logan GreenCo-founder of LyftJen WangDeal Operations Manager at Felicis VenturesArturo LitvinHead of Global Portfolio Development at Intel CapitalKevin ThauInvestor at Spark CapitalErica DelamareInvestor at DaphniDanielle RomanowskiExecutive Assistant at Sapphire Ventures

+ 431 more

Also attended Cornell University1,266

Jenny LeeSenior Managing Partner at Granite AsiaNeeraj AgrawalGeneral Partner at Battery VenturesJohn ZimmerCo-founder of LyftMichelle FernandesInvestor at Index VenturesMike ZakInvestor at CRV (Charles River Ventures)Micah RosenbloomGeneral Partner at Founder Collective

+ 1,260 more

Shared employers

Also worked at Decoy Therapeutics Inc.2

David ArthurChief Executive Officer, President at Salarius PharmaceuticalsPAUL LAMMERS, MD, MScExecutive Officer, Director at Triumvira Immunologics

Also worked at Nocion Therapeutics, Inc.2

Lu HanPartner at Lumira VenturesFreddie DearPrincipal at Monograph Capital Partners

Also worked at Acorda Therapeutics, Inc.4

Rachel Tsunemoto Hislop, PhDPrincipal, Director of Research at Two Bear CapitalMichelle HuieFounder at ShopDotChris KenneyChief Medical Officer at Xenon PharmaKaitlin KestenbergChief Operating Officer & Senior Vice President of Compliance at Admabiologics

Also worked at Pulmatrix Inc.2

Todd BazemoreExecutive Officer at KALA BIOMARK IWICKIExecutive Officer, Director at Civitas Therapeutics